1,220 presentations on ulcerative colitis (UC) and Crohn’s disease (CD), with Real-World Evidence (RWE), quality of life (QoL), and endoscopic remission as top themes. Takeda, Janssen, and Pfizer's studies focused on RWE, randomized trials, and mucosal healing, respectively.
The ECCO 2020-2022 report features 1,220 presentations focused on ulcerative colitis (UC) and Crohn’s disease (CD), with key themes including Real-World Evidence (RWE), quality of life (QoL), and endoscopic remission. These themes reflect the growing emphasis on using real-world data to supplement clinical trials, assessing patient-reported outcomes, and evaluating the effectiveness of therapies in clinical practice.
Takeda: Takeda’s presentations primarily centered around RWE in UC and CD, showcasing studies on the effectiveness of treatments like darvadstrocel for perianal fistulas and vedolizumab in UC. These studies underscored the importance of real-world evidence in understanding treatment impacts beyond clinical trials, particularly in managing complex cases such as Crohn's perianal fistulas.
Janssen: Janssen’s research focused on randomized studies, particularly on the use of anti-TNF and anti-IL-23 therapies in inflammatory bowel disease (IBD). Their work on ustekinumab in both Crohn’s and UC patients demonstrated long-term safety and efficacy, especially in patients new to biologic therapy. Key findings also highlighted the persistent burden of disease in patients despite biologic therapy, emphasizing the need for targeted treatments based on disease location.
Pfizer: Pfizer’s studies highlighted mucosal healing and Phase 3 trials, particularly focusing on the efficacy of tofacitinib in UC. Several studies from the OCTAVE Open program revealed that long-term use of tofacitinib significantly improved health-related quality of life (HRQoL) for patients, even for those who had previously failed anti-TNF therapy. Tofacitinib’s role in improving symptoms like rectal bleeding and stool frequency after dose escalation was also a significant finding.
Endoscopic Remission: This was a frequently discussed outcome across studies, reflecting its growing importance as a key measure of disease control in UC and CD.
Quality of Life (QoL): Numerous presentations emphasized the impact of symptoms such as bowel urgency and fecal incontinence on patients' daily lives, underscoring the need for therapies that address both clinical and patient-reported outcomes.
RWE's Increasing Role: Across all presentations, RWE played a critical role in validating the effectiveness of therapies in real-world settings, with companies like Takeda leading the way in using real-world data to guide treatment decisions and improve patient outcomes.
In summary, the ECCO 2020-2022 report reflects a shift towards incorporating patient-centered outcomes, real-world evidence, and advanced therapeutic approaches like biologics and stem cell treatments, with a strong focus on achieving and maintaining remission in UC and CD.